News und Analysen

DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:

• 
  Steven Pacelli, Executive Vice President, Strategy and

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases

American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases

Regulatory News:

Vifor Pharma today announced a commercial partnership with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to jointly

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today

Veeva Systems (NYSE:VEEV) will announce financial results for its third quarter which ended October 31, 2019 after the market close on November 26, 2019. Veeva will host a conference call and

Veeva Systems (NYSE:VEEV) today announced that Almirall selected multichannel Veeva CRM to deliver seamless customer experience across all channels as it shifts business focus to specialty

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report

Veeva Systems (NYSE:VEEV) today announced it has completed its acquisition of Crossix Solutions. Trusted by more than 200 pharmaceutical brands, Crossix provides privacy-safe U.S. patient data and

IMV Inc. (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the third quarter

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Erweiterung seines QIAseg-NGS-Portfolios bekannt. Das Unternehmen bietet künftig einen eintägigen Workflow für die simultane

Waters Corporation (NYSE:WAT) announced today that its ACQUITY™ Advanced Polymer Chromatography™ (APC™) System is the first fully solvent-compatible UltraPerformance Liquid Chromatography

The Medicines Company (NASDAQ:MDCO) today announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2019. For the quarter, revenue was $668.0 million, an increase of 14.1% from $585.3

Regulatory News:

Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced the availability of its new

Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 first quarter ended Sept. 30, 2019.

All results presented in the following release reflect those of continuing

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company discovering and developing a pipeline of novel drug candidates targeting ion channels, announced today

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2019.

Third Quarter 2019 Highlights:

• 
  Revenue grew 49% versus the same quarter of

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2019, and provided an update on Clovis’ clinical development programs and regulatory and

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will